Arabian International Healthcare Holding Company
TADAWUL:9530.SR
37.6 (SAR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SAR.
| 2024 Q2 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 274.1 | 490.962 | 245.481 | 315.962 | 157.981 | 427.461 | 213.717 | 215.239 | 107.62 | 369.301 | 184.651 | 249.239 | 124.619 | 625.043 | 312.521 | 193.646 | 96.823 |
| Cost of Revenue
| 212.1 | 369.65 | 181.916 | 257.1 | 126.528 | 314.061 | 157.009 | 174.439 | 87.246 | 283.507 | 141.754 | 191.514 | 95.757 | 465.604 | 232.802 | 154.705 | 77.353 |
| Gross Profit
| 62 | 121.312 | 63.565 | 58.862 | 31.453 | 113.4 | 56.707 | 40.8 | 20.373 | 85.794 | 42.897 | 57.725 | 28.862 | 159.439 | 79.719 | 38.941 | 19.471 |
| Gross Profit Ratio
| 0.226 | 0.247 | 0.259 | 0.186 | 0.199 | 0.265 | 0.265 | 0.19 | 0.189 | 0.232 | 0.232 | 0.232 | 0.232 | 0.255 | 0.255 | 0.201 | 0.201 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 15.912 | 15.912 | 13.442 | 13.442 | 11.774 | 11.774 | 9.667 | 9.667 | 6.316 | 6.316 | 7.965 | 7.965 | 7.822 | 7.822 | 7.955 | 7.955 |
| Selling & Marketing Expenses
| 0 | 20.057 | 20.057 | 18.982 | 18.982 | 17.029 | 17.029 | 18.342 | 18.342 | 16.062 | 16.062 | 15.137 | 15.137 | 16.776 | 16.776 | 16.019 | 16.019 |
| SG&A
| 78.4 | 71.869 | 38.844 | 61.587 | 32.816 | 56.529 | 26.235 | 57.718 | 28.832 | 25.093 | 12.547 | 48.328 | 24.164 | 50.17 | 25.085 | 49.925 | 24.962 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 5.146 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 78.4 | 71.869 | 20.613 | 61.587 | 31.913 | 51.382 | 24.462 | 57.718 | 25.423 | 25.093 | 1.652 | 48.328 | 20.043 | 50.17 | 3.784 | 49.925 | 24.429 |
| Operating Income
| -16.4 | 49.444 | 29.466 | -2.725 | 0.446 | 62.018 | 33.298 | -16.918 | -6.506 | 60.701 | 34.407 | 9.396 | 6.14 | 109.268 | 54.408 | -10.983 | -3.835 |
| Operating Income Ratio
| -0.06 | 0.101 | 0.12 | -0.009 | 0.003 | 0.145 | 0.156 | -0.079 | -0.06 | 0.164 | 0.186 | 0.038 | 0.049 | 0.175 | 0.174 | -0.057 | -0.04 |
| Total Other Income Expenses Net
| -10.1 | 21.384 | 4.808 | -12.145 | -7.759 | -10.427 | -7.913 | -0.173 | -0.583 | 14.816 | 6.414 | -2.675 | -0.092 | 22.576 | 16.716 | -9.228 | -7.394 |
| Income Before Tax
| -26.5 | 70.828 | 34.274 | -14.87 | -7.313 | 51.591 | 25.385 | -17.091 | -7.089 | 75.517 | 40.821 | 6.722 | 6.048 | 131.845 | 71.124 | -20.211 | -11.229 |
| Income Before Tax Ratio
| -0.097 | 0.144 | 0.14 | -0.047 | -0.046 | 0.121 | 0.119 | -0.079 | -0.066 | 0.204 | 0.221 | 0.027 | 0.049 | 0.211 | 0.228 | -0.104 | -0.116 |
| Income Tax Expense
| 6 | 6.707 | 3.353 | 4.867 | 2.434 | 4.4 | 2.193 | 6.5 | 3.25 | 4.424 | 2.212 | 7 | 3.5 | 15.5 | 7.75 | 8.5 | 4.25 |
| Net Income
| -31.9 | 60.889 | 30.445 | -22.801 | -11.401 | 52.078 | 20.576 | -20.678 | -10.339 | 77.218 | 38.609 | 5.096 | 2.548 | 126.748 | 63.374 | -30.958 | -15.479 |
| Net Income Ratio
| -0.116 | 0.124 | 0.124 | -0.072 | -0.072 | 0.122 | 0.096 | -0.096 | -0.096 | 0.209 | 0.209 | 0.02 | 0.02 | 0.203 | 0.203 | -0.16 | -0.16 |
| EPS
| -1.61 | 3.08 | 1.54 | -1.15 | -0.58 | 2.32 | 1.03 | -1.03 | -0.52 | 3.86 | 1.93 | 0.25 | 0.13 | 6.34 | 24.72 | -1.55 | -309.58 |
| EPS Diluted
| -1.61 | 3.08 | 1.54 | -1.15 | -0.58 | 1.03 | 1.03 | -1.03 | -0.52 | 3.86 | 1.93 | 0.25 | 0.13 | 6.34 | 24.72 | -1.55 | -309.58 |
| EBITDA
| -15.8 | 58.579 | 32.625 | 3.424 | 2.021 | 34.107 | 34.107 | -13.546 | -4.82 | 64.271 | 35.626 | 13.06 | 7.972 | 112.91 | 54.566 | -7.095 | -1.891 |
| EBITDA Ratio
| -0.058 | 0.119 | 0.133 | 0.011 | 0.013 | 0.08 | 0.16 | -0.063 | -0.045 | 0.174 | 0.193 | 0.052 | 0.064 | 0.181 | 0.175 | -0.037 | -0.02 |